E K A Millar

Summary

Affiliation: Garvan Institute of Medical Research
Country: Australia

Publications

  1. pmc The expression of the ubiquitin ligase SIAH2 (seven in absentia homolog 2) is mediated through gene copy number in breast cancer and is associated with a basal-like phenotype and p53 expression
    Peter Chan
    Department of Pathology, Peter MacCallum Cancer Centre, Locked Bag 1 A Beckett Street, Melbourne, Victoria 8006, Australia
    Breast Cancer Res 13:R19. 2011
  2. pmc Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers
    Huiling Xu
    Research Division, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett Street, Melbourne, VIC 8006, Australia
    Breast Cancer Res 13:R9. 2011
  3. pmc BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast
    E K A Millar
    Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales 2010, Australia
    Br J Cancer 100:123-33. 2009
  4. doi request reprint Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel
    Ewan K A Millar
    Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, New South Wales 2010, Australia
    J Clin Oncol 27:4701-8. 2009
  5. pmc Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53
    E K A Millar
    Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, New South Wales 2010, Australia
    Br J Cancer 105:272-80. 2011
  6. doi request reprint Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer
    C G Roberts
    Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia
    Oncogene 30:3186-97. 2011
  7. pmc Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome
    E K A Millar
    Cancer Research Program, Garvan Institute of Medical Research, Sydney, New South Wales, Australia
    Oncogene 28:1812-20. 2009

Collaborators

  • E A Musgrove
  • J L Dean
  • Peter H Graham
  • G Delaney
  • Robert L Sutherland
  • J Lin
  • Sandra A O'Toole
  • A J Butt
  • Huiling Xu
  • Stephen B Fox
  • Catriona M McNeil
  • Peter Chan
  • C G Roberts
  • Max Yan
  • Jennifer Patra
  • Sigrid Swagemakers
  • G M Lehrbach
  • Nic Waddell
  • Michael J McKay
  • Yuqian Yan
  • Robert G Ramsay
  • Katie T Huang
  • Jonathan M Tomaszewski
  • M Pinese
  • Sandra Verschoor
  • Christina S F Wong
  • Jaclyn E Sceneay
  • David D Bowtell
  • Andreas Möller
  • Mira C P Liu
  • Alexander Dobrovic
  • R A McCloy
  • P Tobelmann
  • Peter van der Spek
  • C M McNeil
  • Jorge S Reis-Filho
  • Rachael Natrajan

Detail Information

Publications7

  1. pmc The expression of the ubiquitin ligase SIAH2 (seven in absentia homolog 2) is mediated through gene copy number in breast cancer and is associated with a basal-like phenotype and p53 expression
    Peter Chan
    Department of Pathology, Peter MacCallum Cancer Centre, Locked Bag 1 A Beckett Street, Melbourne, Victoria 8006, Australia
    Breast Cancer Res 13:R19. 2011
    ..We investigated the frequency and expression pattern of SIAH2 in two independent cohorts of sporadic breast cancers...
  2. pmc Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers
    Huiling Xu
    Research Division, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett Street, Melbourne, VIC 8006, Australia
    Breast Cancer Res 13:R9. 2011
    ..We assessed its prognostic and predictive power in a cohort of in situ and invasive breast cancers, and its effect on chemosensitivity in vitro...
  3. pmc BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast
    E K A Millar
    Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales 2010, Australia
    Br J Cancer 100:123-33. 2009
    ..A high BAG-1 expression predicts improved patient outcome in ER+ breast carcinoma. This may reflect both a better definition of the hormone-responsive phenotype and a concurrent increased sensitivity to tamoxifen...
  4. doi request reprint Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel
    Ewan K A Millar
    Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, New South Wales 2010, Australia
    J Clin Oncol 27:4701-8. 2009
    ..To determine the clinical utility of intrinsic molecular phenotype after breast-conserving therapy (BCT) with lumpectomy and whole-breast irradiation with or without a cavity boost...
  5. pmc Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53
    E K A Millar
    Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, New South Wales 2010, Australia
    Br J Cancer 105:272-80. 2011
    ..In all, 498 patients with invasive breast cancer from a randomised trial of BCT with or without tumour bed radiation boost were assessed using IHC...
  6. doi request reprint Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer
    C G Roberts
    Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia
    Oncogene 30:3186-97. 2011
    ..Moreover, they provide a convincing rationale for exploring new therapeutic approaches involving endocrine and non-endocrine therapies that target apoptotic pathways as an effective strategy for tackling endocrine refractory disease...
  7. pmc Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome
    E K A Millar
    Cancer Research Program, Garvan Institute of Medical Research, Sydney, New South Wales, Australia
    Oncogene 28:1812-20. 2009
    ..Thus, specific cyclin D1 isoforms are associated with discrete forms of breast cancer and high cyclin D1b protein levels hold prognostic potential...